Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on BGMD, FOLD, PPHM and TSL Issued by the Bedford Report

FOLD, BGMD
Free Research Reports on BGMD, FOLD, PPHM and TSL Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=970845&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 01/04/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

BG Medicine, Inc. (NASDAQ: BGMD) shares soared 18.5 percent on nearly 3 million shares traded Thursday. The company has announced that their first automated version of the BGM Galectin-3 blood test has obtained a CE Mark.

Find out more about BG Medicine including full access to the free equity report at: www.BedfordReport.com/BGMD

Amicus Therapeutics, Inc. (NASDAQ: FOLD) shares have rebounded over 30 percent in the past week. The company has reported that their Chairman and CEO will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013.

Find out more about Amicus Therapeutics including full access to the free equity report at: www.BedfordReport.com/FOLD

Peregrine Pharmaceuticals (NASDAQ: PPHM) holds a portfolio of innovative monoclonal antibodies in clinical trials, focused on the treatment and diagnosis of cancer. Zacks has recently upgraded the company to an "outperform" rating and has a price target of $1.50.

Find out more about Peregrine Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/PPHM

Trina Solar Limited (NYSE: TSL) shares surged 18 percent on over 10 million shares traded Thursday. After a dismal 2012 Chinese solar stocks have surged in 2013 on optimism that China's urbanization plan will create new energy demand in 2013.

Find out more about Trina Solar including full access to the free equity report at: www.BedfordReport.com/TSL

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today